Sections

Sections Paroxysmal Nocturnal Hemoglobinuria
Overview
Presentation
DDx
Workup
Treatment
Medication
Questions & Answers
Media Gallery
References

Overview

Practice Essentials

Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell (HSC) disease. It is a rare, chronic, debilitating disorder that most frequently presents in early adulthood and usually continues throughout the patient's life. PNH usually presents as hemolytic anemia, thrombosis, and smooth muscle dystonias, as well as bone marrow failure in some cases. PNH results in the death of approximately 50% of affected individuals due to thrombotic complications. Until recently, no specific therapy was available.

PNH is caused by somatic mutations in PIGA (which encodes phosphatidylinositol N-acetylglucosaminyltransferase subunit A) in one or more HSC clones. The gene product of PIGA is required for the biosynthesis of glycosylphosphatidylinositol (GPI) anchors; thus, PIGA mutations lead to a deficiency of GPI-anchored proteins, such as complement decay-accelerating factor (also known as CD55) and CD59 glycoprotein (CD59), which are both complement inhibitors. Clinical manifestations of PNH occur when a HSC clone carrying somatic PIGA mutations acquires a growth advantage and differentiates, generating mature blood cells that are deficient of GPI-anchored proteins. The loss of CD55 and CD59 renders PNH erythrocytes susceptible to intravascular hemolysis, which can lead to thrombosis and to much of the morbidity and mortality of PNH. The accumulation of anaphylatoxins (such as C5a) from complement activation might also have a role.

The name of the disorder is a descriptive term for the clinical consequence of red blood cell (RBC) breakdown with release of hemoglobin into the urine, which manifests most prominently as dark-colored urine in the morning (see image below).

This series of containers holds urine of a patient with paroxysmal nocturnal hemoglobinuria, showing the episodic nature of the dark urine (hemoglobinuria) during intravascular hemolysis, usually occurring at night. Early morning urine is cola-colored. This may occur at different times of the day and vary from patient to patient. Permission to use this image has been granted by the American Society of Hematology Slide Bank, 3rd edition.

View Media Gallery

The term "nocturnal" refers to the belief that hemolysis is triggered by acidosis during sleep and activates complement to hemolyze an unprotected and abnormal RBC membrane. However, this supposition was later disproved. Hemolysis has been shown to occur throughout the day and is not actually paroxysmal, but the concentration of urine overnight produces the dramatic change in color.

PNH has been referred to as "the great impersonator" because of the variety of signs and symptoms observed during its initial manifestation and course. This variety reflects the contributions of the following three underlying pathophysiologic events^{[1, 2, 3, 4, 5]}:

An acquired intracorpuscular hemolytic anemia due to the abnormal susceptibility of the RBC membrane to the hemolytic activity of complement
Thromboses in large vessels, such as hepatic, abdominal, cerebral, and subdermal veins
A deficiency in hematopoiesis that may be mild or severe, such as pancytopenia in an aplastic anemia state

The triad of hemolytic anemia, pancytopenia, and thrombosis makes PNH a unique clinical syndrome.

The principal studies used to establish the diagnosis of PNH are flow cytometry of peripheral blood and bone marrow analysis. Flow cytometry measures the percentage of cells with the deficiency in complement-regulating surface proteins that underlies PNH; bone marrow analysis differentiates classic PNH from PNH secondary to other bone marrow disorders. (See Workup ).

Pegcetacoplan, eculizumab, and ravulizumab are approved for treatment of PNH. These monoclonal antibodies are targeted inhibitors of complement that alleviate the hemolysis associated with PNH and its sequelae, dramatically improving symptoms, improving quality of life, and eliminating complications of PNH; however, they do not alter the underlying defect of the disease. Allogeneic hematopoietic stem cell transplantation is curative but it requires a histocompatible donor and is associated with significant morbidity and mortality, so it is reserved for severe cases of PNH with aplastic anemia or transformation to leukemia. See Treatment.

For patient education information, see Anemia.

Pathophysiology

Paroxysmal nocturnal hemoglobinuria (PNH) was previously classified as purely an acquired hemolytic anemia due to a hematopoietic stem cell mutation defect. This classification was abandoned because of the observation that surface proteins were missing not only in the RBC membrane but also in all blood cells, including the platelets and white cells.

The common denominator in the disease, a biochemical defect, appears to be a genetic mutation leading to the inability to synthesize the glycosyl-phosphatidylinositol (GPI) anchor that binds these proteins to cell membranes.^{[5, 6, 7]}The corresponding gene PIGA (phosphatidylinositol glycan class A) in the X chromosome can have several mutations, from deletions to point mutations.^[8]

Due to its location on the X chromosome, and X inactivation in female somatic cells, only one mutation is required in either males or females to abolish the expression of GPI-linked proteins. Most type II PNH cells (total lack of GPI-linked protein) are due to a frame shift mutation occurring in the early hematopoietic progenitor cells, resulting in the same mutation in all blood cell lines.

The essential group of membrane proteins that are lacking in all hematopoietic cells in PNH are called complement-regulating surface proteins, including the decay-accelerating factor (DAF), or CD55^[9]; homologous restriction factor (HRF), or C8 binding protein; and membrane inhibitor of reactive lysis (MIRL), or CD59.^[10]All of these proteins interact with complement proteins, particularly C3b and C4b, dissociate the convertase complexes of the classic and alternative pathways, and halt the amplification of the activation process.

The absence of these regulating proteins results in uncontrolled amplification of the complement system. This leads to intravascular destruction of the RBC membrane, to varying degrees. See the image below.

In paroxysmal nocturnal hemoglobinuria (PNH), the absence of anchor proteins that bind complement-regulating proteins (eg, CD55, CD59) to the surface of red blood cells (RBCs) leaves these RBCs susceptible to destruction by the complement membrane attack complex (MAC). Image courtesy of Haematologica. 2010 April;95(4).

View Media Gallery

Breakdown of RBC membranes by complement leads to the release of hemoglobin into the circulation. Hemoglobin is bound to haptoglobin for efficient clearance from the circulation. After saturating the haptoglobin, free hemoglobin circulates and binds irreversibly with nitric oxide (NO), depleting NO levels in peripheral blood.

Because NO regulates smooth muscle tone, depletion of NO levels leads to smooth muscle contraction, with consequent vasoconstriction, constriction of the gut, and pulmonary hypertension. Resultant symptoms may include the following:

Abdominal pain
Bloating
Back pain
Headaches
Esophageal spasms
Erectile dysfunction
Fatigue

Progressive chronic kidney disease can occur after several years of hemoglobinuria from the acute tubulonecrosis effects of heme and iron (pigment nephropathy), decreased renal perfusion from renal vein thrombosis, and tubular obstruction with pigment casts. Patients with PNH experience a high incidence (40%) of thrombotic events (mostly venous) in large vessels (cerebral, hepatic, portal, mesenteric, splenic, and renal veins) and, most recently recognized, arterial thrombosis.

The pathophysiology of thrombophilia in PNH is not fully understood, but the increased incidence during hemolytic episodes suggest a direct relationship with the hemolytic process. Increased procoagulant and fibrinolytic activity, suggesting increased fibrin generation and turnover, increased plasma levels of urokinase-type plasminogen activator and platelets deficient in GPI-linked proteins activated by complement, have been implicated. However, none of these identified platelet and coagulation abnormalities can fully explain the hypercoagulable state in PNH.

Bone marrow failure is defined as peripheral cytopenias associated with decreased hematopoiesis. Bone marrow dysfunction is present in all patients with PNH, even when peripheral blood counts are normal and the bone marrow is hypercellular. The degree of marrow failure may vary from severe aplastic anemia to a decrease in the number of hematopoietic stem cells. Bone marrow failure is possibly due to similar destruction by complement, but the cause or causes are still poorly understood.

Venous thrombosis usually manifests as a sudden catastrophic complication, with severe abdominal pain, a rapidly enlarging liver, and ascites (Budd-Chiari syndrome). This thrombosis may be due to a lack of CD59 on platelet membranes, which induces platelet aggregation and is highly thrombogenic, particularly in the venous system.

Deficient hematopoiesis may occur due to diminished blood cell production by a hypoplastic bone marrow; thus, patients have a 10-20% chance of developing aplastic anemia in their course. In turn, PNH eventually develops in 5% of patients with aplastic anemia.^{[8, 11]}The nature of the pathogenetic link between those two diseases is still unknown.

Pathogenesis

When intravascular hemolysis occurs, RBCs release hemoglobin (Hb) into the plasma. This free Hb is rapidly dimerized and bound by serum protein haptoglobin and rapidly removed by macrophages, which then degrades it after endocytosis. Since haptoglobin is not recycled, large amounts of free Hb can deplete the body's supply, leaving the excess Hb free in the plasma.

When the capacity to manage and degrade free Hb during acute or chronic hemolysis is reached, levels of Hb and heme increase in the plasma and urine. Plasma Hb has the ability to scavenge nitric oxide (NO), resulting in rapid consumption of NO and clinical sequelae of NO depletion. NO plays a major role in vascular homeostasis and has been shown to be a critical regulator of basal and stress-mediated smooth muscle relaxation and vasomotor tone, endothelial adhesion, and platelet activation and aggregation.

Thus, the clinical consequences of excessive cell-free plasma Hb levels during intravascular hemolysis or the administration of Hb preparations include dystonias involving the gastrointestinal, cardiovascular, pulmonary, and urogenital systems, as well as clotting disorders. Many of the clinical sequelae of intravascular hemolysis in a prototypic hemolytic disease, PNH, are readily explained by Hb-mediated NO scavenging.

Paroxysms or episodes of symptoms occur during sudden and marked increases in the rate of intravascular hemolysis. These episodes can be precipitated by infections, drugs, or trauma or they can occur spontaneously. During paroxysms, PNH patients exhibit symptoms consistent with smooth muscle perturbation through the release of Hb and NO scavenging, including abdominal pain, esophageal spasms, and erectile dysfunction.

NO also plays an important role in the maintenance of normal platelet functions through the down-regulation of platelet aggregation and adhesion and the regulation of molecules in the coagulation cascade. Accordingly, the long-term consumption of NO by plasma Hb has been implicated in the formation of clots in PNH patients.^[12]

Thrombosis is the most common cause of death in persons with PNH, accounting for 50% of the mortality from the disease. The most frequent sites of thrombosis include the hepatic, pulmonary, cerebral, and deep and superficial veins, as well as the inferior vena cava. Approximately 15%-20% of thrombosis in PNH is arterial.^[13]Interestingly, there is a close correlation between thrombosis and a large PNH clone, and clone size correlates with hemolytic rates.

The reason for the propensity for thrombosis is not entirely clear. Intravascular hemolysis may provide altered membrane surfaces upon which coagulation may be initiated.

More likely, it is the effect of the activation of complement on platelets and perhaps endothelial cells. In platelets, the deposition of C9 complexes on the surface stimulates their removal by vesiculation; these vesicles are very thrombogenic. Because PNH platelets lack the mechanism for down-regulating C9 deposition (ie, CD59), even a minimal stimulus from activated complement results in a greatly increased production of these vesicles.^[14]

Etiology

For some time, paroxysmal nocturnal hemoglobinuria (PNH) has been known to result from somatic mutations in the PIGA gene, which encodes phosphatidylinositol glycan class A (PIGA). These mutations result in hematopoietic stem cells that are deficient in glycosyl-phosphatidylinositol anchor protein (GPI-AP). Nonmalignant clonal expansion of one or several of these stem cells leads to clinical PNH.

Shen et al have identified additional somatic mutations associated with PNH. These mutations are in genes known to be involved in myeloid neoplasm pathogenesis, including TET2, SUZ12, U2AF1, and JAK2. Clonal analysis indicated that these additional mutations arose either as a subclone within the PIGA-mutant population or had occurred prior to PIGA mutation.^[15]

The clinical pathology in PNH may actually be an epiphenomenon resulting from an adaptive response to injury, such as an immune attack on hematopoietic stem cells.

In PNH, the peripheral blood and bone marrow is a mosaic composed of GPI-AP+ and GPI-AP– cells; with GPI-AP–, cells can be derived from multiple mutant stem cells. The GPI-AP– mutant cells may appear to dominate hematopoiesis in PNH by providing a proliferative advantage under some pathologic conditions. For example, if damage to stem cells causing bone marrow failure is mediated through a GPI-linked surface molecule, the PNH cells lacking these molecules will survive. The close association of PNH with aplastic anemia and myelodysplastic syndrome (MDS) suggests that the selection process arises as a consequence of this specific type of bone marrow injury.

Epidemiology

Paroxysmal nocturnal hemoglobinuria (PNH) incidence is estimated at 1–1.5 cases per million individuals worldwide, but might be higher in certain regions. The disease occurs more frequently in countries in Asia (for example, Japan, Korea and China) than in western countries (the United States, Spain and the United Kingdom). The International PNH Registry was established in 2003 to collect comprehensive data on the natural history of PNH and can provide some epidemiology data.^{[16, 17]}

Attempts to determine the incidence more accurately and to learn more about the natural course of the disease are currently in progress under the auspices of the PNH Registry—"a worldwide collection of data aiming at improving and sharing the understanding of PNH for a better management of patients with PNH". Patients of any age with a clinical diagnosis of PNH (by any applicable diagnostic method) or a detectable fraction of PNH-affected blood cells (that is, a PNH clone) of ≥0.01% of all blood cells are eligible for inclusion.

As of June 30, 2012, 1610 patients from 273 centers in 25 countries were enrolled; of these patients, 92.5% were from Europe and North America and 87.5% were of White ethnicity. No definitive biological data exist to fully explain this distribution; furthermore, there may be bias in the registry. The remaining patients were of Asian or Pacific Island descent (5%), African descent (3.5%), native/Aboriginal descent (0.2%), or of other or unknown ethnicity (3.9%).

A limitation of the data from the International PNH Registry is that information on PNH is not available from all countries. Furthermore, many patients enrolled in the International PNH Registry have aplastic anemia as their primary diagnosis, as the registry allows inclusion of patients with > 0.01% PNH granulocytes. Thus, these prevalence rates are not only based on patients with hemolytic PNH.

Race

Specific clinical manifestations of PNH might vary in different ethnicities. PNH-associated thrombotic events occur in up to 30% of patients in western countries, compared with < 15% of patients in Asian countries. The differences of PNH among races were shown in a study that compared 176 patients from the United States and 209 patients from Japan.^[18]White US patients were younger and had significantly more classic manifestations of the disease, including thrombosis, hemoglobinuria, and infection, whereas Asian patients were older, with more marrow aplasia and a smaller PNH clone. Survival analysis showed a similar death rate in each group, although the causes of death were different, with more thrombotic deaths seen in the US patients. Japanese patients had a longer mean survival time (32.1 vs 19.4 y), but Kaplan-Meier survival curves were not significantly different.^[18]

Other geographic ethnic differences were observed in the thrombosis incidence in 64 patients with classic PNH.^[19]The investigators found that African Americans (n = 11) and Latin Americans (n = 8) had a higher risk or rate of thrombosis by Cox regression analysis and that this had an impact on length of survival compared with other patients (n = 45).^[18]

The epidemiology of PNH-associated bone marrow failure is not as well described in these studies. However, given the overall increased prevalence of aplastic anemia in Asian countries compared with western Europe and the United States, one could hypothesize that PNH-associated bone marrow failure is more common in Asian patients than is thrombosis associated with PNH.^{[20, 21]}

Sex- and Age-related Demographics

Men and women are affected equally with PNH, and no familial tendencies exist.

PNH may occur at any age, from children (10%) as young as 2 years to adults as old as 83 years, but median age at the time of diagnosis was 42 years (range, 16-75 y) in an English series of 80 consecutive patients.^[22]In childhood through adolescence, patients with PNH presented with more of the primary features of aplastic anemia than the otherwise healthy adult population. Other complications, such as infections and thrombosis, occurred with equal frequency in all age groups.

Prognosis

The prognosis in patients with paroxysmal nocturnal hemoglobinuria (PNH) is variable, depending on the severity of symptoms and the presence of complications. An aplastic phase is a serious prognostic factor, because the resulting pancytopenia and thrombosis of hepatic, abdominal, and cerebral veins can have life-threatening consequences. Prophylactic anticoagulation has not been shown to be of benefit because of a lack of data from a clinical trial setting.

The disease process of PNH is insidious and has a chronic course, with a median survival of about 10.3 years. Morbidity depends on the variable expressions of hemolysis, bone marrow failure, and thrombophilia that define the severity and clinical course of the disease.

A study of the first 1610 patients enrolled in the International PNH Registry found that overall, 16% of patients had a history of thrombotic events and 14% a history of impaired kidney function. Frequently reported symptoms included the following^[23]:

Fatigue (80%)
Dyspnea (64%)
Hemoglobinuria (62%)
Abdominal pain (44%)
Chest pain (33%)

Patients also reported impairment in quality of life from their disease, with 17% stating that they were not working or were working less because of PNH.

In several large studies, the main cause of death in patients with PNH was venous thrombosis, followed by complications of bone marrow failure; however, spontaneous long-term remission or leukemic transformation of the PNH clone has been reported and well documented.

The median survival after diagnosis was 10 years in a series of 80 consecutive patients seen at the Hammersmith Hospital in London who were treated with supportive measures, such as oral anticoagulant therapy after an established thrombosis, and transfusions.^[22] Sixty patients died; of 48 patients whose cause of death was known, 28 died from venous thrombosis or hemorrhage. Thirty-one individuals (39%) had one or more episodes of venous thrombosis during their illness.^[22] No leukemic transformations occurred in this series.

Twenty-two of the 80 patients (28%) survived for 25 years.^[22] Of the 35 patients who survived for 10 years or more, 12 had spontaneous clinical recovery; no PNH-affected cells were found among the RBCs or neutrophils during their prolonged remission, but a few PNH-affected lymphocytes were detectable in 3 of 4 patients tested.^[22]

Clinical Presentation

Shah N, Bhatt H. Paroxysmal Nocturnal Hemoglobinuria. 2023 Jan. [QxMD MEDLINE Link]. [Full Text].
Brodsky RA. Paroxysmal Nocturnal Hemoglobinuria. Hoffman R, Benz EJ Jr, Silberstein LE, Heslop HE, Weitz JI, Anastasi J, Salama ME, Abutalib SA, eds. Hematology: Basic Principles and Practice. 7th ed. Philadelphia, PA: Elsevier; 2017. 415-24.
DeZern AE, Brodsky RA. Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia. Hematol Oncol Clin North Am. 2015 Jun. 29 (3):479-94. [QxMD MEDLINE Link].
Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017 May 18. 3:17028. [QxMD MEDLINE Link].
Roth A, Duhrsen U, Schrezenmeier H, Schubert J. [Paroxysmal nocturnal hemoglobinuria (PNH). Pathogenesis, diagnosis and treatment]. Dtsch Med Wochenschr. 2009 Feb. 134(9):404-9. [QxMD MEDLINE Link].
Merrill SA, Brodsky RA. Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria. Hematology Am Soc Hematol Educ Program. 2018 Nov 30. 2018 (1):371-376. [QxMD MEDLINE Link].
Brodsky RA. Complement in hemolytic anemia. Blood. 2015 Nov 26. 126 (22):2459-65. [QxMD MEDLINE Link]. [Full Text].
Nagarajan S, Brodsky RA, Young NS, Medof ME. Genetic defects underlying paroxysmal nocturnal hemoglobinuria that arises out of aplastic anemia. Blood. 1995 Dec 15. 86(12):4656-61. [QxMD MEDLINE Link]. [Full Text].
Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet. 2009 Feb 28. 373(9665):759-67. [QxMD MEDLINE Link].
Ruiz-Delgado GJ, Vazquez-Garza E, Mendez-Ramirez N, Gomez-Almaguer D. Abnormalities in the expression of CD55 and CD59 surface molecules on peripheral blood cells are not specific to paroxysmal nocturnal hemoglobinuria. Hematology. 2009 Feb. 14(1):33-7. [QxMD MEDLINE Link].
Young NS. Hematopoietic cell destruction by immune mechanisms in acquired aplastic anemia. Semin Hematol. 2000 Jan. 37(1):3-14. [QxMD MEDLINE Link].
Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005 Apr 6. 293(13):1653-62. [QxMD MEDLINE Link].
Griffin M, Munir T. Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician's guide. Ther Adv Hematol. 2017 Mar. 8 (3):119-126. [QxMD MEDLINE Link]. [Full Text].
Rosse W. A new way to prevent thrombosis. Blood. 2007. 110:3821.
Shen W, Clemente MJ, Hosono N, Yoshida K, Przychodzen B, Yoshizato T, et al. Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria. J Clin Invest. 2014 Oct 1. 124(10):4529-38. [QxMD MEDLINE Link]. [Full Text].
Socié G, Schrezenmeier H, Muus P, Lisukov I, Röth A, Kulasekararaj A, et al. Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH Registry. Intern Med J. 2016 Sep. 46 (9):1044-53. [QxMD MEDLINE Link].
Yu F, Du Y, Han B. A comparative analysis of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria between Asia and Europe/America. Int J Hematol. 2016 Jun. 103 (6):649-54. [QxMD MEDLINE Link].
Nishimura J, Kanakura Y, Ware RE, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004 May. 83(3):193-207. [QxMD MEDLINE Link].
Araten DJ, Thaler HT, Luzzatto L. High incidence of thrombosis in African-American and Latin-American patients with Paroxysmal Nocturnal Haemoglobinuria. Thromb Haemost. 2005 Jan. 93(1):88-91. [QxMD MEDLINE Link].
Issaragrisil S, Kaufman DW, Anderson T, Chansung K, Leaverton PE, Shapiro S, et al. The epidemiology of aplastic anemia in Thailand. Blood. 2006 Feb 15. 107 (4):1299-307. [QxMD MEDLINE Link].
Young NS, Kaufman DW. The epidemiology of acquired aplastic anemia. Haematologica. 2008 Apr. 93 (4):489-92. [QxMD MEDLINE Link]. [Full Text].
Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995 Nov 9. 333(19):1253-8. [QxMD MEDLINE Link].
Schrezenmeier H, Muus P, Socié G, Szer J, Urbano-Ispizua A, Maciejewski JP, et al. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica. 2014 May. 99(5):922-9. [QxMD MEDLINE Link]. [Full Text].
Socie G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet. 1996 Aug 31. 348(9027):573-7. [QxMD MEDLINE Link].
Nishimura J, Kanakura Y, Ware RE, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004 May. 83(3):193-207. [QxMD MEDLINE Link].
Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005 Dec 1. 106(12):3699-709. [QxMD MEDLINE Link]. [Full Text].
Kim JS, Jang JH, Yoon SS, Lee JH, Kim YK, Jo DY, et al. Distinct subgroups of paroxysmal nocturnal hemoglobinuria (PNH) with cytopenia: results from South Korean National PNH Registry. Ann Hematol. 2015 Sep 29. [QxMD MEDLINE Link].
Dulau-Florea A, Maric I, Calvo KR, Braylan RC. Detection of paroxysmal nocturnal hemoglobinuria (PNH) in bone marrow aspirates^☆. Semin Hematol. 2019 Jan. 56 (1):65-68. [QxMD MEDLINE Link].
Borowitz MJ, Craig FE, Digiuseppe JA, et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom. 2010 Jul. 78(4):211-30. [QxMD MEDLINE Link].
Rosse WF, Dacie JV. The role of complement in the sensitivity of the paroxysmal nocturnal haemoglobinuria red cell to immune lysis. Bibl Haematol. 1965. 23:11-8. [QxMD MEDLINE Link].
Rosse WF, Dacie JV. Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. I. The sensitivity of PNH red cells to lysis by complement and specific antibody. J Clin Invest. 1966 May. 45(5):736-48. [QxMD MEDLINE Link]. [Full Text].
Rosse WF, Dacie JV. Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. II. The role of complement components in the increased sensitivity of PNH red cells to immune lysis. J Clin Invest. 1966 May. 45(5):749-57. [QxMD MEDLINE Link]. [Full Text].
Brodsky RA. Stem cell transplantation for paroxysmal nocturnal hemoglobinuria. Haematologica. 2010 Jun. 95(6):855-6. [QxMD MEDLINE Link]. [Full Text].
Cooper JP, Farah RJ, Stevenson PA, Gooley TA, Storb R, Scott BL. Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab. Biol Blood Marrow Transplant. 2019 Jul. 25 (7):1331-1339. [QxMD MEDLINE Link]. [Full Text].
Ebenbichler CF, Wurzner R, Sandhofer AD, Niederwieser D, Dierich MP, Patsch JR. Anti-thymocyte globulin treatment of a patient for paroxysmal nocturnal haemoglobinuria-aplastic anaemia syndrome: complement activation and transient decrease of the PNH clone. Immunobiology. 1996-1997. 196(5):513-21. [QxMD MEDLINE Link].
Röth A, Nishimura JI, Nagy Z, et al. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood. 2020 Mar 19. 135 (12):912-920. [QxMD MEDLINE Link]. [Full Text].
Risitano AM, Marotta S. Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2018 Aug. 93 (4):564-577. [QxMD MEDLINE Link].
Yuan X, Gavriilaki E, Thanassi JA, Yang G, Baines AC, Podos SD, et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica. 2017 Mar. 102 (3):466-475. [QxMD MEDLINE Link]. [Full Text].
Jang JH, Wong L, Ko BS, Yoon SS, Li K, Baltcheva I, et al. Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study. Blood Adv. 2022 Aug 9. 6 (15):4450-4460. [QxMD MEDLINE Link].
Risitano AM, Röth A, Soret J, Frieri C, de Fontbrune FS, Marano L, et al. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. Lancet Haematol. 2021 May. 8 (5):e344-e354. [QxMD MEDLINE Link].
Bomback AS, Kavanagh D, Vivarelli M, Meier M, Wang Y, Webb NJA, et al. Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial. Kidney Int Rep. 2022 Oct. 7 (10):2150-2159. [QxMD MEDLINE Link].
Risitano AM, Kulasekararaj AG, Lee JW, Maciejewski JP, Notaro R, Brodsky R, et al. Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. Haematologica. 2021 Dec 1. 106 (12):3188-3197. [QxMD MEDLINE Link]. [Full Text].
Kulasekararaj AG, Risitano AM, Maciejewski JP, Notaro R, Browett P, Lee JW, et al. Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab. Blood. 2021 Nov 18. 138 (20):1928-1938. [QxMD MEDLINE Link]. [Full Text].
Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, Pessoa V, Gualandro S, Füreder W, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019 Feb 7. 133 (6):530-539. [QxMD MEDLINE Link]. [Full Text].
Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzalez-Fernandez FA, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019 Feb 7. 133 (6):540-549. [QxMD MEDLINE Link]. [Full Text].
Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004 Feb 5. 350(6):552-9. [QxMD MEDLINE Link].
Hill A, Hillmen P, Richards SJ, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood. 2005 Oct 1. 106(7):2559-65. [QxMD MEDLINE Link].
Sicre de Fontbrune F, Peffault de Latour R. Ten Years of Clinical Experience With Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria. Semin Hematol. 2018 Jul. 55 (3):124-129. [QxMD MEDLINE Link].
Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011 Jun 23. 117(25):6786-92. [QxMD MEDLINE Link].
Vaccine Information Statements (VIS):. Serogroup B Meningococcal (MenB) VIS. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/vaccines/hcp/vis/vis-statements/mening-serogroup.html. 8/14/2015; Accessed: April 22, 2023.
Alashkar F, Vance C, Herich-Terhürne D, Preising N, Dührsen U, Röth A. Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab. Ann Hematol. 2017 Apr. 96 (4):589-596. [QxMD MEDLINE Link].
Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011 Jun 23. 117(25):6786-92. [QxMD MEDLINE Link].
Peipert JD, Kulasekararaj AG, Gaya A, Langemeijer SMC, Yount S, Gonzalez-Fernandez FA, et al. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. PLoS One. 2020. 15 (9):e0237497. [QxMD MEDLINE Link]. [Full Text].
Brodsky RA, Peffault de Latour R, Rottinghaus ST, Röth A, Risitano AM, Weitz IC, et al. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica. 2020 Jan 16. [QxMD MEDLINE Link]. [Full Text].
Lee JW, Kulasekararaj AG. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Expert Opin Biol Ther. 2020 Mar. 20 (3):227-237. [QxMD MEDLINE Link].
Tomazos I, Sierra JR, Johnston KM, Cheung A, Brodsky RA, Weitz IC. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab. Hematology. 2020 Dec. 25 (1):327-334. [QxMD MEDLINE Link]. [Full Text].
O'Connell T, Buessing M, Johnson S, Tu L, Thomas SK, Tomazos I. Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria. Pharmacoeconomics. 2020 Sep. 38 (9):981-994. [QxMD MEDLINE Link].
Peipert JD, Kulasekararaj AG, Gaya A, Langemeijer SMC, Yount S, Gonzalez-Fernandez FA, et al. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. PLoS One. 2020. 15 (9):e0237497. [QxMD MEDLINE Link]. [Full Text].
FDA approves ravulizumab-cwvz for paroxysmal nocturnal hemoglobinuria. U.S. Food & Drug Administration. Available at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ravulizumab-cwvz-paroxysmal-nocturnal-hemoglobinuria. December 26, 2018; Accessed: April 22, 2023.
U.S. Food and Drug Administration. FDA approves therapy for pediatric patients with serious rare blood disease. FDA.gov. Available at https://www.fda.gov/drugs/fda-approves-therapy-pediatric-patients-serious-rare-blood-disease. 2021 Jun 07; Accessed: April 22, 2023.
Yenerel MN, Sicre de Fontbrune F, Piatek C, Sahin F, Füreder W, Ortiz S, et al. Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up. Adv Ther. 2023 Jan. 40 (1):211-232. [QxMD MEDLINE Link]. [Full Text].
Hillmen P, Szer J, Weitz I, Röth A, Höchsmann B, Panse J, et al. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2021 Mar 18. 384 (11):1028-1037. [QxMD MEDLINE Link]. [Full Text].
Wong RSM, Navarro-Cabrera JR, Comia NS, Goh YT, Idrobo H, Kongkabpan D, et al. Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria. Blood Adv. 2023 Jun 13. 7 (11):2468-2478. [QxMD MEDLINE Link].
Wong R, Fishman J, Wilson K, Yeh M, Al-Adhami M, Zion A, et al. Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison. Adv Ther. 2023 Apr. 40 (4):1571-1589. [QxMD MEDLINE Link]. [Full Text].
Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013 Jun 20. 121 (25):4985-96; quiz 5105. [QxMD MEDLINE Link].
Kuo GP, Brodsky RA, Kim HS. Catheter-directed thrombolysis and thrombectomy for the Budd-Chiari syndrome in paroxysmal nocturnal hemoglobinuria in three patients. J Vasc Interv Radiol. 2006 Feb. 17 (2 Pt 1):383-7. [QxMD MEDLINE Link].
Singer AL, Locke JE, Stewart ZA, Lonze BE, Hamilton JP, Scudiere JR, et al. Successful liver transplantation for Budd-Chiari syndrome in a patient with paroxysmal nocturnal hemoglobinuria treated with the anti-complement antibody eculizumab. Liver Transpl. 2009 May. 15 (5):540-3. [QxMD MEDLINE Link].
Hillmen P, Elebute M, Kelly R, Urbano-Ispizua A, Hill A, Rother RP, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2010 Aug. 85 (8):553-9. [QxMD MEDLINE Link]. [Full Text].
Hillmen P, Muus P, Dührsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007 Dec 1. 110(12):4123-8. [QxMD MEDLINE Link].
van Bijnen ST, Østerud B, Barteling W, Verbeek-Knobbe K, Willemsen M, van Heerde WL, et al. Alterations in markers of coagulation and fibrinolysis in patients with Paroxysmal Nocturnal Hemoglobinuria before and during treatment with eculizumab. Thromb Res. 2015 Aug. 136 (2):274-81. [QxMD MEDLINE Link].
Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008 Feb 15. 111(4):1840-7. [QxMD MEDLINE Link].
Hillmen P, Elebute M, Kelly R, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2010 Aug. 85(8):553-9. [QxMD MEDLINE Link].
Santarone S, Bacigalupo A, Risitano AM, et al. Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long-term results of a retrospective study on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Haematologica. 2010 Jun. 95(6):983-8. [QxMD MEDLINE Link]. [Full Text].
Saso R, Marsh J, Cevreska L, Szer J, Gale RP, Rowlings PA. Bone marrow transplants for paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1999 Feb. 104(2):392-6. [QxMD MEDLINE Link].
Vallet N, et al; Société Francophone de Greffe de Moelle et Thérapie Cellulaire. Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a retrospective study of 21 patients from SFGM-TC centers. Haematologica. 2018 Mar. 103 (3):e103-e105. [QxMD MEDLINE Link]. [Full Text].
Kelly R, Arnold L, Richards S, et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol. 2010 May. 149(3):446-50. [QxMD MEDLINE Link].
Kelly RJ, Höchsmann B, Szer J, Kulasekararaj A, de Guibert S, Röth A, et al. Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2015 Sep 10. 373 (11):1032-9. [QxMD MEDLINE Link].
Ravulizumab. 2020 Jul 20. [QxMD MEDLINE Link]. [Full Text].
Gembillo G, Siligato R, Cernaro V, Santoro D. Complement Inhibition Therapy and Dialytic Strategies in Paroxysmal Nocturnal Hemoglobinuria: The Nephrologist's Opinion. J Clin Med. 2020 Apr 26. 9 (5):[QxMD MEDLINE Link]. [Full Text].
Babushok DV, Stanley N, Xie HM, Huang H, Bagg A, Olson TS, et al. Clonal Replacement Underlies Spontaneous Remission in Paroxysmal Nocturnal Haemoglobinuria. Br J Haematol. 2017 Feb. 176 (3):487-490. [QxMD MEDLINE Link]. [Full Text].
Hill A, Hillmen P, Richards SJ, Elebute D, Marsh JC, Chan J, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood. 2005 Oct 1. 106 (7):2559-65. [QxMD MEDLINE Link].

Media Gallery

This series of containers holds urine of a patient with paroxysmal nocturnal hemoglobinuria, showing the episodic nature of the dark urine (hemoglobinuria) during intravascular hemolysis, usually occurring at night. Early morning urine is cola-colored. This may occur at different times of the day and vary from patient to patient. Permission to use this image has been granted by the American Society of Hematology Slide Bank, 3rd edition.
The Ham test (acidified serum lysis) establishes the diagnosis of paroxysmal nocturnal hemoglobinuria (PNH), demonstrating a characteristic abnormality of PNH red blood cells by acidified fresh normal serum. Here is a PNH patient's (Pt) red blood cells lysed by normal serum at room temperature (RT) and at 37°C compared with normal red cells (no hemolysis) (control [C]). Heated serum at 56°C inactivates complement and prevents hemolysis in PNH cells. Permission to use this image has been granted by the American Society of Hematology Slide Bank, 3rd edition.
In paroxysmal nocturnal hemoglobinuria (PNH), the absence of anchor proteins that bind complement-regulating proteins (eg, CD55, CD59) to the surface of red blood cells (RBCs) leaves these RBCs susceptible to destruction by the complement membrane attack complex (MAC). Image courtesy of Haematologica. 2010 April;95(4).